PL3466955T3 - Sposób otrzymywania pochodnych oksazolo[4,5-B]pirydyny i tiazolo[4,5-B]pirydyny jako inhibitorów IRAK4 w leczeniu raka - Google Patents

Sposób otrzymywania pochodnych oksazolo[4,5-B]pirydyny i tiazolo[4,5-B]pirydyny jako inhibitorów IRAK4 w leczeniu raka

Info

Publication number: PL3466955T3
Authority: PL; Poland
Prior art keywords: pyridine; irak4; oxazolo; thiazolo; inhibitors
Prior art date: 2014-01-13

Application number

PL18190333T

Other languages

English (en)

Inventor

Venkateshwar Rao Gummadi

Susanta Samajdar

Original Assignee

Aurigene Discovery Technologies Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-01-13

Filing date

2015-01-12

Publication date

2021-06-28

2015-01-12 Application filed by Aurigene Discovery Technologies Limited filed Critical Aurigene Discovery Technologies Limited

2021-06-28 Publication of PL3466955T3 publication Critical patent/PL3466955T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Otolaryngology (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Gastroenterology & Hepatology (AREA)

PL18190333T 2014-01-13 2015-01-12 Sposób otrzymywania pochodnych oksazolo[4,5-B]pirydyny i tiazolo[4,5-B]pirydyny jako inhibitorów IRAK4 w leczeniu raka PL3466955T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
IN158CH2014		2014-01-13
IN3000CH2014		2014-06-20
EP15735499.4A EP3094329B1 (en)	2014-01-13	2015-01-12	Bicyclic heterocyclyl derivatives as irak4 inhibitors
PCT/IB2015/050217 WO2015104688A1 (en)	2014-01-13	2015-01-12	Bicyclic heterocyclyl derivatives as irak4 inhibitors
EP18190333.7A EP3466955B1 (en)	2014-01-13	2015-01-12	Method of preparing oxazolo[4,5-b]pyridine and thiazolo[4,5-b]pyridine derivatives as irak4 inhibitors for treating cancer

Publications (1)

Publication Number	Publication Date
PL3466955T3 true PL3466955T3 (pl)	2021-06-28

Family

ID=53523587

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL20211096.1T PL3805233T3 (pl)	2014-01-13	2015-01-12	ENANCJOMERY (R) I (S) (S)-N-(5-(3-hydroksypirolidyn-1-ylo)-2-morfolinooksazolo[4,5-b]pirydyn-6-ylo)-2-(2-metylopirydyn-4-ylo)oksazolo-4-karboksyamidu jako inhibitory IRAK4 do leczenia nowotworu złośliwego
PL15735499T PL3094329T3 (pl)	2014-01-13	2015-01-12	Bicykliczne pochodne heterocyklilowe jako inhibitory irak4
PL18190333T PL3466955T3 (pl)	2014-01-13	2015-01-12	Sposób otrzymywania pochodnych oksazolo[4,5-B]pirydyny i tiazolo[4,5-B]pirydyny jako inhibitorów IRAK4 w leczeniu raka

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PL20211096.1T PL3805233T3 (pl)	2014-01-13	2015-01-12	ENANCJOMERY (R) I (S) (S)-N-(5-(3-hydroksypirolidyn-1-ylo)-2-morfolinooksazolo[4,5-b]pirydyn-6-ylo)-2-(2-metylopirydyn-4-ylo)oksazolo-4-karboksyamidu jako inhibitory IRAK4 do leczenia nowotworu złośliwego
PL15735499T PL3094329T3 (pl)	2014-01-13	2015-01-12	Bicykliczne pochodne heterocyklilowe jako inhibitory irak4

Country Status (31)

Country	Link
US (8)	US9732095B2 (pl)
EP (4)	EP3094329B1 (pl)
JP (7)	JP6479850B2 (pl)
KR (4)	KR102785576B1 (pl)
CN (2)	CN106456619B (pl)
AU (6)	AU2015205374B2 (pl)
BR (1)	BR112016016158B1 (pl)
CA (1)	CA2935887A1 (pl)
CU (1)	CU24389B1 (pl)
CY (2)	CY1121433T1 (pl)
DK (3)	DK3466955T3 (pl)
EA (2)	EA038748B1 (pl)
ES (3)	ES2846678T3 (pl)
FI (1)	FI3805233T3 (pl)
HR (3)	HRP20240489T1 (pl)
HU (3)	HUE041926T2 (pl)
IL (7)	IL302878B2 (pl)
LT (3)	LT3466955T (pl)
MX (1)	MX359909B (pl)
MY (1)	MY197116A (pl)
NZ (2)	NZ760657A (pl)
PH (2)	PH12016501344A1 (pl)
PL (3)	PL3805233T3 (pl)
PT (3)	PT3094329T (pl)
RS (3)	RS61448B1 (pl)
SG (2)	SG10201811204RA (pl)
SI (3)	SI3094329T1 (pl)
SM (3)	SMT202100063T1 (pl)
TR (1)	TR201815683T4 (pl)
WO (1)	WO2015104688A1 (pl)
ZA (4)	ZA202007274B (pl)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201311888D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compounds
GB201311891D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compound
EP3092226B1 (en)	2014-01-10	2019-03-13	Aurigene Discovery Technologies Limited	Indazole compounds as irak4 inhibitors
LT3466955T (lt)	2014-01-13	2021-02-25	Aurigene Discovery Technologies Limited	Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas
US20180228907A1 (en)	2014-04-14	2018-08-16	Arvinas, Inc.	Cereblon ligands and bifunctional compounds comprising the same
CN108024971A (zh) *	2015-07-15	2018-05-11	奥列基因发现技术有限公司	作为irak-4抑制剂的取代的氮杂化合物
DK3331879T3 (da)	2015-08-04	2020-08-10	Rigel Pharmaceuticals Inc	Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
WO2017148902A1 (de)	2016-03-03	2017-09-08	Bayer Pharma Aktiengesellschaft	Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
TW202340194A (zh)	2017-02-16	2023-10-16	美商基利科學股份有限公司	吡咯并[1,2-b]嗒𠯤衍生物
EP3600270B1 (en) *	2017-03-31	2023-06-14	Aurigene Oncology Limited	Compounds and compositions for treating hematological disorders
US11358948B2 (en)	2017-09-22	2022-06-14	Kymera Therapeutics, Inc.	CRBN ligands and uses thereof
WO2019060742A1 (en)	2017-09-22	2019-03-28	Kymera Therapeutics, Inc	AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
HUE067356T2 (hu) *	2017-10-31	2024-10-28	Curis Inc	IRAK4 inhibitor és BCL-2 inhibitor kombinációban, rák kezelésére való felhasználásra
EP3710443A1 (en)	2017-11-17	2020-09-23	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2019111218A1 (en)	2017-12-08	2019-06-13	Cadila Healthcare Limited	Novel heterocyclic compounds as irak4 inhibitors
IL315310A (en)	2017-12-26	2024-10-01	Kymera Therapeutics Inc	Irak degraders and uses thereof
WO2019140387A1 (en)	2018-01-12	2019-07-18	Kymera Therapeutics, Inc.	Crbn ligands and uses thereof
WO2019140380A1 (en)	2018-01-12	2019-07-18	Kymera Therapeutics, Inc.	Protein degraders and uses thereof
EP3305786A3 (de)	2018-01-22	2018-07-25	Bayer CropScience Aktiengesellschaft	Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
US11542251B2 (en)	2018-02-14	2023-01-03	Dana-Farber Cancer Institute, Inc.	IRAK degraders and uses thereof
WO2020010227A1 (en)	2018-07-06	2020-01-09	Kymera Therapeutics, Inc.	Protein degraders and uses thereof
WO2020010177A1 (en)	2018-07-06	2020-01-09	Kymera Therapeutics, Inc.	Tricyclic crbn ligands and uses thereof
TWI842978B (zh)	2018-07-13	2024-05-21	美商基利科學股份有限公司	衍生物
CN117285467A (zh)	2018-07-31	2023-12-26	罗索肿瘤学公司	喷雾干燥的分散体和制剂
CA3119773A1 (en)	2018-11-30	2020-06-04	Kymera Therapeutics, Inc.	Irak degraders and uses thereof
MA54755A (fr) *	2019-01-18	2021-11-24	Biogen Ma Inc	Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4
PH12022500002A1 (en)	2019-06-28	2023-04-03	Kymera Therapeutics Inc	Irak degraders and uses thereof
WO2021004533A1 (zh) *	2019-07-10	2021-01-14	南京明德新药研发有限公司	作为irak4和btk多靶点抑制剂的噁唑类化合物
WO2021011868A1 (en)	2019-07-17	2021-01-21	Kymera Therapeutics, Inc.	Irak degraders and uses thereof
EP3999508B1 (en)	2019-07-18	2023-08-30	Bristol-Myers Squibb Company	Tricyclic heteroaryl compounds useful as irak4 inhibitors
WO2021011727A1 (en)	2019-07-18	2021-01-21	Bristol-Myers Squibb Company	PYRAZOLO[3,4-d]PYRROLO[1,2-b]PYRIDAZINYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS
US12304916B2 (en)	2019-07-23	2025-05-20	Bristol-Myers Squibb Company	Thienopyridinyl and thiazolopyridinyl compounds useful as IRAK4 inhibitors
WO2021026181A1 (en)	2019-08-06	2021-02-11	Bristol-Myers Squibb Company	Bicyclic heterocyclic compounds useful as irak4 inhibitors
EP3772513A1 (en) *	2019-08-09	2021-02-10	C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening	Shp2 inhibitors
ES3059914T3 (en)	2019-08-13	2026-03-24	Bristol Myers Squibb Co	Bicyclic heteroaryl compounds useful as irak4 inhibitors
WO2021066559A1 (en)	2019-10-02	2021-04-08	Kainos Medicine, Inc.	N-(1h-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient
WO2021119159A1 (en)	2019-12-10	2021-06-17	Kymera Therapeutics, Inc.	Irak degraders and uses thereof
EP4076524A4 (en)	2019-12-17	2023-11-29	Kymera Therapeutics, Inc.	IRAQ DEGRADERS AND USES THEREOF
KR20220145325A (ko)	2019-12-17	2022-10-28	카이메라 쎄라퓨틱스 인코포레이티드	Irak 분해제 및 이의 용도
WO2021158495A1 (en)	2020-02-03	2021-08-12	Bristol-Myers Squibb Company	Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors
IL297050A (en)	2020-04-04	2022-12-01	Pfizer	Methods of treating the 2019 corona virus disease
WO2021204589A1 (en)	2020-04-07	2021-10-14	Bayer Aktiengesellschaft	Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances
WO2021222366A1 (en) *	2020-04-28	2021-11-04	Kymera Therapeutics, Inc.	Irak inhibitors and uses thereof
TW202210483A (zh)	2020-06-03	2022-03-16	美商凱麥拉醫療公司	Irak降解劑之結晶型
IL300310A (en) *	2020-08-03	2023-04-01	Curis Inc	Preparations and methods for treating diseases and disorders
US12064421B2 (en)	2020-11-02	2024-08-20	Boehringer Ingelheim International Gmbh	Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitors
MX2023005591A (es) *	2020-11-18	2023-05-29	Curis Inc	Metodos de tratamiento de enfermedades y trastornos.
CN116745294A (zh) *	2020-12-25	2023-09-12	南京明德新药研发有限公司	酰胺噁唑类化合物
CN116867758A (zh)	2020-12-30	2023-10-10	凯麦拉医疗公司	Irak降解剂和其用途
CN116867494A (zh)	2021-02-15	2023-10-10	凯麦拉医疗公司	Irak4降解剂和其用途
US12171768B2 (en)	2021-02-15	2024-12-24	Kymera Therapeutics, Inc.	IRAK4 degraders and uses thereof
EP4319750A4 (en)	2021-04-08	2025-02-26	Curis, Inc.	COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
KR20240020735A (ko)	2021-05-07	2024-02-15	카이메라 쎄라퓨틱스 인코포레이티드	Cdk2 분해제 및 그 용도
TW202328151A (zh)	2021-09-07	2023-07-16	德商拜耳廠股份有限公司	經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途
TW202328150A (zh)	2021-09-07	2023-07-16	德商拜耳廠股份有限公司	經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途
CA3236265A1 (en)	2021-10-29	2023-05-04	William Leong	Irak4 degraders and synthesis thereof
EP4434981A4 (en) *	2021-12-23	2025-08-20	Hangzhou Polymed Biopharmaceuticals Inc	FIVE- AND SIX-MEMBERED COMPOUND, ITS PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION AND ITS USE
TW202330546A (zh) *	2021-12-31	2023-08-01	香港商愛科諾生物醫藥(香港)有限公司	具有irak4抑制活性的化合物，包含其的藥物組合物，及其應用
CA3243560A1 (en)	2022-01-31	2023-08-03	Kymera Therapeutics, Inc.	Iraqi Degradation Agents and Their Uses
IL315677A (en)	2022-03-23	2024-11-01	Rigel Pharmaceuticals Inc	Pyrimid-2-yl-pyrazole compounds as irak inhibitors
CN120303270A (zh) *	2022-10-13	2025-07-11	凯麦拉医疗公司	Irak4降解剂的盐形式
TW202432563A (zh) *	2022-10-25	2024-08-16	美商凱麥拉醫療公司	Irak降解劑及其用途
WO2025130871A1 (zh) *	2023-12-20	2025-06-26	爱科诺生物医药(香港)有限公司	具有irak4和flt3蛋白双重降解活性的化合物，包含其的药物组合物，及其应用
WO2025208000A1 (en) *	2024-03-29	2025-10-02	Curis, Inc.	Methods of treating cancer in patients with altered protein expression
WO2026005536A1 (ko) *	2024-06-28	2026-01-02	주식회사 대웅제약	신규한 화합물, 및 이를 포함하는 암 또는 자가 면역 질환의 예방 또는 치료용 약학적 조성물
CN119119080A (zh) *	2024-09-06	2024-12-13	上海信诺维生物医药有限公司	一种irak4的蛋白降解剂

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2102367T3 (es)	1990-05-18	1997-08-01	Hoechst Ag	Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion.
DE10023486C1 (de)	2000-05-09	2002-03-14	Schering Ag	Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
US6878714B2 (en)	2001-01-12	2005-04-12	Amgen Inc.	Substituted alkylamine derivatives and methods of use
US20030134836A1 (en)	2001-01-12	2003-07-17	Amgen Inc.	Substituted arylamine derivatives and methods of use
US7189716B2 (en) *	2003-01-03	2007-03-13	Bristol-Myers Squibb Company	Tyrosine kinase inhibitors
WO2004096310A2 (en)	2003-04-25	2004-11-11	Cook, Inc.	Low friction coated marked wire guide for over the wire insertion of a catheter
EP2385041B1 (en)	2003-05-01	2013-09-18	Bristol-Myers Squibb Company	Pyrazole-amine compounds useful as kinase inhibitors
EP1627869B1 (en)	2003-05-20	2012-05-02	Ajinomoto Co., Inc.	Vanilloid receptor modulators
EP1628661A2 (en)	2003-06-05	2006-03-01	Vertex Pharmaceuticals Incorporated	Modulators of vr1 receptor
EP1493795A1 (de)	2003-07-04	2005-01-05	Collano AG	Klebstoffzusammensetzung
MXPA06003949A (es)	2003-10-07	2006-06-27	Renovis Inc	Compuestos amida como ligandos del canal de ion y su uso.
MY145634A (en) *	2003-12-29	2012-03-15	Bristol Myers Squibb Co	Pyrrolotriazine compounds as kinase inhibitors
CA2563941C (en)	2004-04-22	2014-10-07	Bayer Cropscience Lp	Method and composition for controlling weeds with a combination of a preemergent, a post emergent and a three-way broadleaf herbicidal compositions
EP1655297A1 (en)	2004-11-03	2006-05-10	Schering Aktiengesellschaft	Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
US7906533B2 (en)	2004-11-03	2011-03-15	Bayer Schering Pharma Ag	Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
WO2006053227A2 (en)	2004-11-10	2006-05-18	Synta Pharmaceuticals Corp.	Il-12 modulatory compounds
WO2006066174A1 (en)	2004-12-17	2006-06-22	Eli Lilly And Company	Thiazolopyridinone derivates as mch receptor antagonists
DE602005009021D1 (de)	2004-12-17	2008-09-25	Lilly Co Eli	Neue mch-rezeptorantagonisten
EP1674467A1 (en)	2004-12-22	2006-06-28	4Sc Ag	2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
WO2007058626A1 (en)	2005-11-16	2007-05-24	S*Bio Pte Ltd	Indazole compounds
CN101379060B (zh)	2006-02-10	2012-05-23	转化技术制药公司	作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
GB0606429D0 (en)	2006-03-30	2006-05-10	Novartis Ag	Organic compounds
CA2644910C (en)	2006-03-31	2014-01-28	Abbott Laboratories	Indazole compounds
US20080293785A1 (en)	2006-04-11	2008-11-27	Connolly Peter J	Substituted benzothiazole kinase inhibitors
CN101594909A (zh) *	2006-09-07	2009-12-02	比奥根艾迪克Ma公司	用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
EP2061786A2 (en) *	2006-09-07	2009-05-27	Biogen Idec MA Inc.	Indazole derivatives as modulators of interleukin-1 receptor-associated kinase
US20080153810A1 (en)	2006-11-15	2008-06-26	Forest Laboratories Holdings Limited	Indazole derivatives useful as melanin concentrating receptor ligands
KR20090094125A (ko)	2006-12-08	2009-09-03	엑셀리시스, 인코포레이티드	Ｌｘｒ 및 ｆｘｒ 조절자
JP4785881B2 (ja)	2007-02-27	2011-10-05	大塚製薬株式会社	医薬
CA2690557A1 (en)	2007-06-14	2008-12-24	Schering Corporation	Imidazopyrazines as protein kinase inhibitors
WO2009011850A2 (en)	2007-07-16	2009-01-22	Abbott Laboratories	Novel therapeutic compounds
ES2457418T3 (es)	2007-07-16	2014-04-25	Abbvie Inc.	Indazoles, bencisoxazoles y bencisotiazoles como inhibidores de proteína cinasas
CN101790519B (zh)	2007-08-08	2013-10-16	默克雪兰诺有限公司	用于治疗多发性硬化症的结合于鞘氨醇1-磷酸(s1p)的6-氨基-嘧啶-4-羧酰胺衍生物及相关化合物
WO2009102468A1 (en)	2008-02-13	2009-08-20	Cgi Pharmaceuticals, Inc.	6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
WO2010008847A2 (en)	2008-06-24	2010-01-21	Takeda Pharmaceutical Company Limited	Pi3k/m tor inhibitors
CN102281919A (zh)	2008-11-19	2011-12-14	先灵公司	二酰基甘油酰基转移酶的抑制剂
WO2010071819A1 (en) *	2008-12-19	2010-06-24	Schering Corporation	Bicyclic heterocyclic derivatives and methods of use thereof
WO2010072599A1 (en)	2008-12-23	2010-07-01	F. Hoffmann-La Roche Ag	Dihydropyridone ureas as p2x7 modulators
US8765747B2 (en)	2009-06-12	2014-07-01	Dana-Farber Cancer Institute, Inc.	Fused 2-aminothiazole compounds
MX2012001974A (es)	2009-08-19	2012-04-11	Ambit Biosciences Corp	Compuestos de biarilo y metodos de uso de los mismos.
JP2012254939A (ja)	2009-10-07	2012-12-27	Astellas Pharma Inc	オキサゾール化合物
WO2011046954A1 (en)	2009-10-13	2011-04-21	Ligand Pharmaceuticals Inc.	Hematopoietic growth factor mimetic small molecule compounds and their uses
US8822447B2 (en)	2010-04-22	2014-09-02	Janssen Pharmaceutica Nv	Indazole compounds useful as ketohexokinase inhibitors
US20130053382A1 (en)	2010-04-30	2013-02-28	Sunil Paliwal	Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1)
RS56332B1 (sr)	2010-06-24	2017-12-29	Chemocentryx Inc	Antagonisti c5ar
CN110003219A (zh)	2010-07-13	2019-07-12	弗·哈夫曼-拉罗切有限公司	作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
RU2632900C2 (ru)	2010-11-19	2017-10-11	Лиганд Фармасьютикалс Инкорпорейтед	Гетероциклические амины и их применение
BR112013015460B1 (pt)	2010-12-20	2022-01-25	Merck Serono S.A.	Derivados de indazolil triazol, kit, e composição farmacêutica
EP2696873B1 (en)	2011-04-12	2022-08-03	The United States of America, as represented by The Secretary, Department of Health and Human Services	Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
WO2013042137A1 (en)	2011-09-19	2013-03-28	Aurigene Discovery Technologies Limited	Bicyclic heterocycles as irak4 inhibitors
AU2012322095B2 (en)	2011-10-14	2017-06-29	Ambit Biosciences Corporation	Heterocyclic compounds and use thereof as modulators of type III receptor tyrosine kinases
JP6073343B2 (ja)	2011-10-20	2017-02-01	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅＬＬＣ	サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
US9221809B2 (en) *	2011-10-31	2015-12-29	Merck Sharp & Dohme Corp.	Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
GB201119401D0 (en)	2011-11-10	2011-12-21	Ucb Pharma Sa	Therapeutic agents
KR101385603B1 (ko)	2012-05-17	2014-04-21	한국원자력의학원	벤조티아졸 유도체 및 암 치료를 위한 그의 용도
WO2014003483A1 (en)	2012-06-29	2014-01-03	Hanmi Pharm. Co., Ltd.	Fused pyrimidine derivatives having inhibitory activity on fms kinases
WO2014011902A1 (en)	2012-07-11	2014-01-16	Nimbus Iris, Inc.	Irak inhibitors and uses thereof
JP6372666B2 (ja)	2012-11-03	2018-08-15	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	サイトメガロウイルスの阻害剤
EP2999470B1 (en)	2013-05-22	2017-08-16	Children's Hospital Medical Center	Combination therapy for mds
TWI652014B (zh)	2013-09-13	2019-03-01	美商艾佛艾姆希公司	雜環取代之雙環唑殺蟲劑
TWI667233B (zh)	2013-12-19	2019-08-01	德商拜耳製藥公司	新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
EP3092226B1 (en)	2014-01-10	2019-03-13	Aurigene Discovery Technologies Limited	Indazole compounds as irak4 inhibitors
LT3466955T (lt)	2014-01-13	2021-02-25	Aurigene Discovery Technologies Limited	Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas
US9452986B2 (en)	2014-02-06	2016-09-27	Abbvie Inc.	6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use
AU2015275730A1 (en)	2014-06-20	2016-12-15	Aurigene Discovery Technologies Limited	Substituted indazole compounds as IRAK4 inhibitors
JO3705B1 (ar)	2014-11-26	2021-01-31	Bayer Pharma AG	إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
TW201701879A (zh)	2015-04-30	2017-01-16	拜耳製藥公司	Ｉｒａｋ４抑制劑組合
JP2018524372A (ja)	2015-07-15	2018-08-30	アウリジーンディスカバリーテクノロジーズリミテッド	Ｉｒａｋ−４阻害剤としてのインダゾール及びアザインダゾール化合物
CN108024971A (zh)	2015-07-15	2018-05-11	奥列基因发现技术有限公司	作为irak-4抑制剂的取代的氮杂化合物
DK3331879T3 (da)	2015-08-04	2020-08-10	Rigel Pharmaceuticals Inc	Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
US20170035881A1 (en)	2015-10-19	2017-02-09	Acerta Pharma B.V.	Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor
WO2018081738A1 (en)	2016-10-28	2018-05-03	Children's Hospital Medical Center	Treatment of diseases associated with activated irak
EP3600270B1 (en) *	2017-03-31	2023-06-14	Aurigene Oncology Limited	Compounds and compositions for treating hematological disorders
HUE067356T2 (hu)	2017-10-31	2024-10-28	Curis Inc	IRAK4 inhibitor és BCL-2 inhibitor kombinációban, rák kezelésére való felhasználásra
CA3119773A1 (en)	2018-11-30	2020-06-04	Kymera Therapeutics, Inc.	Irak degraders and uses thereof
PH12022500002A1 (en)	2019-06-28	2023-04-03	Kymera Therapeutics Inc	Irak degraders and uses thereof
IL300310A (en)	2020-08-03	2023-04-01	Curis Inc	Preparations and methods for treating diseases and disorders
MX2023005591A (es)	2020-11-18	2023-05-29	Curis Inc	Metodos de tratamiento de enfermedades y trastornos.
EP4319750A4 (en)	2021-04-08	2025-02-26	Curis, Inc.	COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
JP2025516501A (ja)	2022-05-11	2025-05-30	キュリス，インコーポレイテッド	Ｉｒａｋ４修飾化合物による疾患及び障害の治療
AU2024281302A1 (en)	2023-06-01	2025-12-11	Curis, Inc.	Methods of treating cancer in subjects with prior immune checkpoint inhibitor exposure
KR20260018053A (ko)	2023-06-01	2026-02-06	쿠리스 인코퍼레이션	Bcl2 억제제에 노출 이력이 없는 대상체의 암 치료 방법

2015
- 2015-01-12 LT LTEP18190333.7T patent/LT3466955T/lt unknown
- 2015-01-12 PL PL20211096.1T patent/PL3805233T3/pl unknown
- 2015-01-12 IL IL302878A patent/IL302878B2/en unknown
- 2015-01-12 ES ES18190333T patent/ES2846678T3/es active Active
- 2015-01-12 KR KR1020237029626A patent/KR102785576B1/ko active Active
- 2015-01-12 CN CN201580013752.4A patent/CN106456619B/zh active Active
- 2015-01-12 EA EA201891917A patent/EA038748B1/ru unknown
- 2015-01-12 LT LTEP20211096.1T patent/LT3805233T/lt unknown
- 2015-01-12 SM SM20210063T patent/SMT202100063T1/it unknown
- 2015-01-12 RS RS20210039A patent/RS61448B1/sr unknown
- 2015-01-12 CU CU2016000111A patent/CU24389B1/es unknown
- 2015-01-12 EP EP15735499.4A patent/EP3094329B1/en active Active
- 2015-01-12 SI SI201530477T patent/SI3094329T1/sl unknown
- 2015-01-12 CN CN202010147212.8A patent/CN111362966B/zh active Active
- 2015-01-12 SM SM20180680T patent/SMT201800680T1/it unknown
- 2015-01-12 EP EP23214923.7A patent/EP4353324A3/en active Pending
- 2015-01-12 NZ NZ760657A patent/NZ760657A/en unknown
- 2015-01-12 KR KR1020227014075A patent/KR102574390B1/ko active Active
- 2015-01-12 FI FIEP20211096.1T patent/FI3805233T3/fi active
- 2015-01-12 DK DK18190333.7T patent/DK3466955T3/da active
- 2015-01-12 PL PL15735499T patent/PL3094329T3/pl unknown
- 2015-01-12 MX MX2016009013A patent/MX359909B/es active IP Right Grant
- 2015-01-12 RS RS20181355A patent/RS58024B1/sr unknown
- 2015-01-12 SG SG10201811204RA patent/SG10201811204RA/en unknown
- 2015-01-12 TR TR2018/15683T patent/TR201815683T4/tr unknown
- 2015-01-12 SI SI201531483T patent/SI3466955T1/sl unknown
- 2015-01-12 HU HUE15735499A patent/HUE041926T2/hu unknown
- 2015-01-12 JP JP2016563278A patent/JP6479850B2/ja active Active
- 2015-01-12 RS RS20240415A patent/RS65437B1/sr unknown
- 2015-01-12 MY MYPI2021007377A patent/MY197116A/en unknown
- 2015-01-12 EP EP20211096.1A patent/EP3805233B1/en active Active
- 2015-01-12 SG SG11201605486WA patent/SG11201605486WA/en unknown
- 2015-01-12 ES ES20211096T patent/ES2975436T3/es active Active
- 2015-01-12 EA EA201691428A patent/EA031913B1/ru unknown
- 2015-01-12 LT LTEP15735499.4T patent/LT3094329T/lt unknown
- 2015-01-12 KR KR1020257009008A patent/KR20250049413A/ko active Pending
- 2015-01-12 IL IL284952A patent/IL284952B/en unknown
- 2015-01-12 AU AU2015205374A patent/AU2015205374B2/en active Active
- 2015-01-12 HR HRP20240489TT patent/HRP20240489T1/hr unknown
- 2015-01-12 US US15/111,000 patent/US9732095B2/en active Active
- 2015-01-12 SM SM20240142T patent/SMT202400142T1/it unknown
- 2015-01-12 HR HRP20181795TT patent/HRP20181795T1/hr unknown
- 2015-01-12 EP EP18190333.7A patent/EP3466955B1/en active Active
- 2015-01-12 DK DK20211096.1T patent/DK3805233T3/da active
- 2015-01-12 WO PCT/IB2015/050217 patent/WO2015104688A1/en not_active Ceased
- 2015-01-12 PT PT15735499T patent/PT3094329T/pt unknown
- 2015-01-12 SI SI201532008T patent/SI3805233T1/sl unknown
- 2015-01-12 ES ES15735499.4T patent/ES2692852T3/es active Active
- 2015-01-12 HU HUE20211096A patent/HUE066261T2/hu unknown
- 2015-01-12 BR BR112016016158-0A patent/BR112016016158B1/pt active IP Right Grant
- 2015-01-12 IL IL294895A patent/IL294895B2/en unknown
- 2015-01-12 DK DK15735499.4T patent/DK3094329T3/en active
- 2015-01-12 PL PL18190333T patent/PL3466955T3/pl unknown
- 2015-01-12 NZ NZ722019A patent/NZ722019A/en unknown
- 2015-01-12 CA CA2935887A patent/CA2935887A1/en active Pending
- 2015-01-12 PT PT202110961T patent/PT3805233T/pt unknown
- 2015-01-12 HU HUE18190333A patent/HUE052252T2/hu unknown
- 2015-01-12 IL IL311677A patent/IL311677B2/en unknown
- 2015-01-12 PT PT181903337T patent/PT3466955T/pt unknown
- 2015-01-12 IL IL317922A patent/IL317922A/en unknown
- 2015-01-12 KR KR1020167021713A patent/KR102392684B1/ko active Active
2016
- 2016-07-03 IL IL246575A patent/IL246575B/en active IP Right Grant
- 2016-07-07 PH PH12016501344A patent/PH12016501344A1/en unknown
2017
- 2017-08-02 US US15/667,173 patent/US10047104B2/en active Active
2018
- 2018-08-03 US US16/054,512 patent/US10640517B2/en active Active
- 2018-11-20 AU AU2018267569A patent/AU2018267569B2/en active Active
- 2018-12-21 CY CY20181101382T patent/CY1121433T1/el unknown
2019
- 2019-02-06 JP JP2019019229A patent/JP6750053B2/ja active Active
- 2019-12-11 IL IL271364A patent/IL271364B/en unknown
- 2019-12-17 AU AU2019283795A patent/AU2019283795B2/en active Active
2020
- 2020-02-19 US US16/795,394 patent/US10995100B2/en active Active
- 2020-03-13 PH PH12020500529A patent/PH12020500529A1/en unknown
- 2020-06-25 JP JP2020109507A patent/JP6977111B2/ja active Active
- 2020-11-23 ZA ZA2020/07274A patent/ZA202007274B/en unknown
- 2020-11-23 ZA ZA2020/07276A patent/ZA202007276B/en unknown
- 2020-11-23 ZA ZA2020/07273A patent/ZA202007273B/en unknown
- 2020-11-23 ZA ZA2020/07275A patent/ZA202007275B/en unknown
2021
- 2021-01-19 HR HRP20210094TT patent/HRP20210094T1/hr unknown
- 2021-01-29 CY CY20211100076T patent/CY1123936T1/el unknown
- 2021-04-30 US US17/245,611 patent/US11691987B2/en active Active
- 2021-06-08 AU AU2021203761A patent/AU2021203761B2/en active Active
- 2021-11-10 JP JP2021183016A patent/JP7262553B2/ja active Active
2023
- 2023-04-11 JP JP2023063800A patent/JP7601937B2/ja active Active
- 2023-04-28 US US18/141,008 patent/US11981685B2/en active Active
- 2023-09-01 AU AU2023222987A patent/AU2023222987B2/en active Active
2024
- 2024-04-08 US US18/629,313 patent/US12410193B2/en active Active
- 2024-12-05 JP JP2024211949A patent/JP7775430B2/ja active Active
2025
- 2025-08-04 US US19/289,386 patent/US20250361244A1/en active Pending
- 2025-09-04 AU AU2025226775A patent/AU2025226775A1/en active Pending
- 2025-11-12 JP JP2025191819A patent/JP2026027431A/ja active Pending

Also Published As

Publication number	Publication date
KR102785576B1 (ko)	2025-03-21
ZA202007276B (en)	2025-05-28
US11981685B2 (en)	2024-05-14
IL317922A (en)	2025-02-01
US20250361244A1 (en)	2025-11-27
SI3805233T1 (sl)	2024-07-31
PT3805233T (pt)	2024-04-15
SMT201800680T1 (it)	2019-01-11
ES2846678T3 (es)	2021-07-28
CY1121433T1 (el)	2020-05-29
AU2019283795B2 (en)	2021-04-01
US10995100B2 (en)	2021-05-04
ZA202007275B (en)	2025-05-28
JP2019077729A (ja)	2019-05-23
IL311677A (en)	2024-05-01
SG10201811204RA (en)	2019-01-30
US10640517B2 (en)	2020-05-05
US20240294547A1 (en)	2024-09-05
EA031913B1 (ru)	2019-03-29
FI3805233T3 (fi)	2024-04-17
EP3805233A1 (en)	2021-04-14
IL311677B1 (en)	2025-02-01
KR20250049413A (ko)	2025-04-11
IL311677B2 (en)	2025-06-01
BR112016016158B1 (pt)	2022-12-13
PH12020500529A1 (en)	2021-07-26
EP4353324A2 (en)	2024-04-17
IL302878B1 (en)	2024-05-01
JP2020164546A (ja)	2020-10-08
HRP20210094T1 (hr)	2021-03-05
CY1123936T1 (el)	2022-05-27
EA201691428A1 (ru)	2016-12-30
US20180370988A1 (en)	2018-12-27
AU2015205374A1 (en)	2016-07-28
LT3805233T (lt)	2024-05-10
KR102392684B1 (ko)	2022-04-29
NZ760657A (en)	2022-07-01
EP3466955B1 (en)	2020-12-16
AU2021203761A1 (en)	2021-07-08
NZ722019A (en)	2022-07-01
CN106456619A (zh)	2017-02-22
AU2025226775A1 (en)	2025-09-25
AU2023222987B2 (en)	2025-06-05
PT3466955T (pt)	2021-01-29
IL271364A (en)	2020-01-30
WO2015104688A1 (en)	2015-07-16
IL284952A (en)	2021-08-31
ZA202007274B (en)	2023-11-29
AU2018267569A1 (en)	2018-12-06
IL284952B (en)	2022-08-01
JP7775430B2 (ja)	2025-11-25
JP2023085526A (ja)	2023-06-20
HK1231410A1 (zh)	2017-12-22
HUE041926T2 (hu)	2019-06-28
JP6479850B2 (ja)	2019-03-06
JP7601937B2 (ja)	2024-12-17
SI3094329T1 (sl)	2019-02-28
MX359909B (es)	2018-10-16
JP7262553B2 (ja)	2023-04-21
AU2019283795A1 (en)	2020-01-16
EP3805233B1 (en)	2024-03-06
CA2935887A1 (en)	2015-07-16
TR201815683T4 (tr)	2018-11-21
DK3094329T3 (en)	2018-11-19
SI3466955T1 (sl)	2021-05-31
SMT202100063T1 (it)	2021-03-15
IL246575A0 (en)	2016-08-31
RS61448B1 (sr)	2021-03-31
JP2022024021A (ja)	2022-02-08
AU2023222987A1 (en)	2023-09-21
SG11201605486WA (en)	2016-08-30
KR20160115934A (ko)	2016-10-06
HRP20181795T1 (hr)	2019-01-25
JP2025032208A (ja)	2025-03-11
DK3466955T3 (da)	2021-02-01
KR20230129622A (ko)	2023-09-08
HUE052252T2 (hu)	2021-04-28
US12410193B2 (en)	2025-09-09
ES2975436T3 (es)	2024-07-05
US10047104B2 (en)	2018-08-14
MX2016009013A (es)	2017-01-23
JP2017502088A (ja)	2017-01-19
US20230331740A1 (en)	2023-10-19
ES2692852T3 (es)	2018-12-05
IL246575B (en)	2019-12-31
JP6977111B2 (ja)	2021-12-08
DK3805233T3 (da)	2024-04-15
EP3466955A1 (en)	2019-04-10
EA201891917A1 (ru)	2019-02-28
PH12016501344A1 (en)	2016-08-15
US20200190112A1 (en)	2020-06-18
HUE066261T2 (hu)	2024-07-28
PT3094329T (pt)	2018-11-26
US20220056046A1 (en)	2022-02-24
IL302878B2 (en)	2024-09-01
EP3094329A4 (en)	2017-05-31
CN111362966A (zh)	2020-07-03
US20160340366A1 (en)	2016-11-24
RS65437B1 (sr)	2024-05-31
EA038748B1 (ru)	2021-10-14
HRP20240489T1 (hr)	2024-07-05
JP2026027431A (ja)	2026-02-18
IL294895B1 (en)	2023-06-01
CU20160111A7 (es)	2017-03-03
CN106456619B (zh)	2020-03-27
RS58024B1 (sr)	2019-02-28
EP3094329A1 (en)	2016-11-23
PL3805233T3 (pl)	2024-06-10
CN111362966B (zh)	2022-03-11
AU2015205374B2 (en)	2018-08-23
MY197116A (en)	2023-05-26
IL271364B (en)	2021-08-31
IL294895B2 (en)	2023-10-01
LT3094329T (lt)	2018-11-26
PL3094329T3 (pl)	2019-03-29
KR20220061266A (ko)	2022-05-12
LT3466955T (lt)	2021-02-25
EP3094329B1 (en)	2018-09-26
CU24389B1 (es)	2019-04-04
AU2021203761B2 (en)	2023-06-01
US20180022758A1 (en)	2018-01-25
JP6750053B2 (ja)	2020-09-02
AU2018267569B2 (en)	2019-09-26
US9732095B2 (en)	2017-08-15
EP4353324A3 (en)	2024-07-03
KR102574390B1 (ko)	2023-09-04
IL294895A (en)	2022-09-01
IL302878A (en)	2023-07-01
ZA202007273B (en)	2023-11-29
BR112016016158A2 (pt)	2017-08-08
US11691987B2 (en)	2023-07-04
SMT202400142T1 (it)	2024-05-14

Publication	Publication Date	Title
PL3466955T3 (pl)	2021-06-28	Sposób otrzymywania pochodnych oksazolo[4,5-B]pirydyny i tiazolo[4,5-B]pirydyny jako inhibitorów IRAK4 w leczeniu raka
HRP20180697T1 (hr)	2018-06-01	Spojevi imidazo[4,5-c]kinolin-2-ona i njihova upotreba za liječenje raka
LT3675854T (lt)	2025-04-25	Piperidinilindolo dariniai, skirti c3 glomerulopatijai gydyti
ZA201803742B (en)	2020-08-26	Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
DK3194388T3 (da)	2019-09-23	Imidazo[4,5-c]pyridin afledte ssao-inhibitorer
IL258828A (en)	2018-06-28	Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
GB201519406D0 (en)	2015-12-16	Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
HRP20180788T1 (hr)	2018-06-29	[1,2,4]triazolo[4,3-b]piridazini za uporabu za liječenje proliferativnih bolesti
LT3230289T (lt)	2019-10-10	7-(morfolinil)-2-(n-piperazinil)metiltieno[2, 3-c]piridino dariniai kaip priešvėžiniai vaistai
IL251166B (en)	2020-06-30	Imidazo–[4,5–c]pyridine derivatives as inhibitors of ssao
HK1197910B (en)	2018-06-08	Substituted pyridine derivatives useful in the treatment of cancer
HK1197910A (en)	2015-02-27	Substituted pyridine derivatives useful in the treatment of cancer
HK40015946A (en)	2020-09-04	Oxazole derivatives for use in the treatment of cancer
HK40015947A (en)	2020-09-04	Oxazole derivatives for use in the treatment of cancer
HK1255487A1 (en)	2019-08-16	Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
EP3125903A4 (en)	2017-11-15	Method for use of homopiperazinium compounds in the treatment of cancer